Stocks · News reference
Telomir Pharmaceuticals Publishes Peer-Reviewed Preclinical Data In Biomedicine & Pharmacotherapy Titled "Telomir-Zn Restores Glucose Homeostasis and Reduces Insulin Resistance in a Diet-Induced Zebrafish Model of Type 2 Diabetes"
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Telomir Pharmaceuticals, Inc. (TELO)
Filed: 2026-08-10 AccNo: 0001493152-26-036742 Size: 245 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Telomir Pharmaceuticals Appoints Andriy Mushak As Fractional CFO Following Departure Of CFO Alan Weichselbaum, Effective June 6, 2026